← Back to Clinical Trials
Recruiting NCT07226401

NCT07226401 Virtual Village for Young Parents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07226401
Status Recruiting
Phase
Sponsor RTI International
Condition Gender-based Violence
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-11-11
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age 21 Years
Study Type INTERVENTIONAL
Interventions
Virtual Safe Dates for Young ParentsHealthSmart

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-11-11 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project will study virtual delivery of Safe Dates for Young Parents (SDYP), a 10-session, group-based intimate partner violence (IPV) prevention program tailored for adolescents and young adults who are pregnant or parenting. This program has the potential to improve the health and well-being of young parents and their children, and virtual delivery may improve participants' ability to attend. The main questions it aims to answer are: (1) Is it feasible and acceptable to implement SDYP in a virtual setting? (2) Are SDYP participants less likely to experience IPV than participants in an alternate health education program? Participants will be invited to a series of virtual program sessions for either SDYP or a health education program focused on physical activity and nutrition and will be asked to complete surveys before the programs begin and up to 6 months later.

Eligibility Criteria

Inclusion Criteria: Pregnant or parenting youth (Pilot RCT participants) * Aged 16-21 years. * Currently pregnant, partner of a pregnant person, or parenting a child (i.e., have contact with child at least once per week). * Able to speak and read English. * Willing and able to provide written informed consent. * Willing and able to provide adequate contact/locator information. Facilitators (IDI participants) * Aged 18 years or older. * Trained and served as a facilitator of the virtual SDYP intervention. * Able to speak and read English. * Able and willing to provide verbal informed consent. Exclusion Criteria (Pilot RCT participants): * Has any other condition that, in the opinion of the PI or their designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. * Currently participating or will be participating in a violence prevention education program in the next 3 months. * Previously participated in the Empowering Young Parents study.

Contact & Investigator

Central Contact

Marni Kan, PhD

✉ mkan@rti.org

📞 919-485-2756

Frequently Asked Questions

Who can join the NCT07226401 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, up to 21 Years, studying Gender-based Violence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07226401 currently recruiting?

Yes, NCT07226401 is actively recruiting participants. Contact the research team at mkan@rti.org for enrollment information.

Where is the NCT07226401 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT07226401 clinical trial?

NCT07226401 is sponsored by RTI International. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology